Advancing Our Clinical Perspectives in Haematology: What Is Your Approach?

Chairperson:

Sarah Jarvis¹

Speakers:

Gunnar Birgegård,² Tamara Lado Cives,³ Sélim Aractingi,⁴ Chiaki Nakaseko,⁵ Claire Harrison,⁶ Melania Moreno Vega,⁷ Jean‑Jacques Kiladjian,⁸ Salah Alimam,⁹ Manuel Martinez‑Sellés¹⁰

1. Primary Care Physician and Healthcare Reporter, UK
2. Division of Medical Sciences, Haematology, Uppsala University, Uppsala, Sweden
3. Servicio de Hematología Clinica, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
4. Department of Dermatology, Cochin Hôpital, Paris, France
5. Department of Hematology, Chiba University Hospital, Chiba, Japan
6. Department of Cancer and Haematology, Guy’s and St. Thomas’ Hospital, London, UK
7. Negrin University Hospital, Gran Canaria, Las Palmas, Spain
8. Clinical Investigations Centre, Hôpital Saint‑Louis, Paris, France
9. Department of Haematology, Guy’s and St. Thomas’ Hospital, London, UK
10. Department of Cardiology, Gregorio Marañon Hospital, Madrid, Spain

Disclosure:

Sarah Jarvis has no conflicts of interests to disclose. Gunnar Birgegård has received speaker’s fees/honoraria from Shire and Vifor Pharma. Tamara Lado Cives has no conflicts of interest to disclose.  Sélim Aractingi has received research support from Leo Pharma, speaker’s fees/honoraria from Shire, Novartis, and AbbVie and has served on advisory boards for Shire and Novartis. Chiaki Nakaseko has  received research support from Bristol‑Myers Squibb, Pfizer, Kyowa‑Hakko Kirin, Takeda, Chugai, Otsuka, Shionogi, and Asahikasei‑Pharm and speaker’s fees/honoraria from Pfizer, Celgene, Bristol‑Myers Squibb,  and Shire. Claire Harrison has received research support from Novartis, speaker’s fees/honoraria from Novartis, Shire, CTI, Baxalta, Gilead, and Incyte and has served on advisory boards for CTI, Baxalta, and Novartis. Melania Moreno Vega has no conflicts of interests to disclose. Jean‑Jacques Kiladjian has received research support from Novartis, speaker’s fees/honoraria from Novartis, Shire, and AOP Orphan and has served on advisory boards for Novartis, Shire, and AOP Orphan. Samah Alimam has no conflicts of  interests to disclose. Manuel Martinez‑Sellés has received research support from Servier, Novartis, and  Pfizer, speaker’s fees/honoraria from Servier, Shire, Novartis, and Pfizer and has served on advisory boards for Shire.

Acknowledgements:

The 11^th New Horizons in Haematology conference was initiated, organised, and  funded by Shire. Medical writing assistance was funded by Shire. The views and opinions expressed are those of the authors as expressed during the conference and not necessarily those of Shire.

Citation:

EMJ Hematol. 2016;4[Suppl 9]:2-9. DOI/10.33590/emjhematol/10311643. https://doi.org/10.33590/emjhematol/10311643.

Keywords:

haematology, NHH11

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.